03:49 AM EDT, 05/03/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) reported a Q1 net loss late Thursday of 2.30 euros ($2.47) per diluted share, compared with a loss of 1.98 euros a year earlier.

Analysts polled by Capital IQ expected a per-share loss of 1.43 euros.

Revenue for the quarter ended March 31 was 95.9 million euros, up from 33.6 million euros a year ago.

Analysts surveyed by Capital IQ expected 79.8 million euros.

Price: 145.26, Change: +4.16, Percent Change: +2.95